Mesenchymal stromal cells 2.0: thinking outside the box.
Mandl GA., Lahrichi M., Matar P., Abusarah J., Farah R., Bikorimana JP.
Narrative Review, published in Front Immunol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Front Immunol (2025)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40909281
- DOI
- 10.3389/fimmu.2025.1657048
Abstract (original English)
Mesenchymal stromal cells (MSCs) are non-hematopoietic progenitor cells that can be derived from a variety of sources including bone marrow and adipose tissues among others. MSCs are plastic adherent and easy to culture ex vivo , making them attractive platforms for cell-based technologies. They have an impressive immunoplasticity and can express a suppressive or inflammatory phenotype depending on their stimuli. While MSCs are mainly used in tissue regeneration or as a tool to suppress unwanted inflammation, their pro-inflammatory phenotype includes their ability to act as antigen presenting cells (APCs). This property, along with their ease of expansion and manipulation, make them excellent candidates as alternatives to dendritic cell-based technologies, especially for cancer vaccination. To generate stable MSCs with an APC-like phenotype, two main venues have been explored: genetic and pharmacological reprogramming. Routes to generating MSC-APCs have shown great promise in therapeutic and prophylactic settings in vivo , demonstrating effective tumor control in multiple murine models. Mechanistically, MSC-APCs appear to be generated in response to reactive oxygen species and endoplasmic reticulum stress. While much remains to be uncovered with respect to their phenotype, these reprogrammed cells show great promise as the next generation of cancer vaccine platforms. Herein, we
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.